Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA
- 1 August 2009
- journal article
- Published by Elsevier BV in Coordination Chemistry Reviews
- Vol. 253 (15-16), 2070-2081
- https://doi.org/10.1016/j.ccr.2009.01.028
Abstract
No abstract availableKeywords
This publication has 123 references indexed in Scilit:
- cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospectsProceedings of the National Academy of Sciences, 2008
- Platinum-based inhibitors of amyloid-β as therapeutic agents for Alzheimer's diseaseProceedings of the National Academy of Sciences, 2008
- New trends for metal complexes with anticancer activityCurrent Opinion in Chemical Biology, 2008
- A potent cytotoxic photoactivated platinum complexProceedings of the National Academy of Sciences, 2007
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Soluble Single-Walled Carbon Nanotubes as Longboat Delivery Systems for Platinum(IV) Anticancer Drug DesignJournal of the American Chemical Society, 2007
- NMR Solution Structure of an Oxaliplatin 1,2-d(GG) Intrastrand Cross-link in a DNA Dodecamer DuplexJournal of Molecular Biology, 2004
- Decreased cisplatin uptake by resistant L1210 leukemia cellsCancer Letters, 1987
- Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitationBiochemistry, 1985
- Reduction of cis-dichlorodiammineplatinum-induced cell inactivation by benzaldehydeEuropean Journal of Cancer and Clinical Oncology, 1984